83 results
8-K
EX-99.1
IMCR
Immunocore Holdings plc
8 May 24
Immunocore reports first quarter financial results and provides a business update
7:13am
million in international regions.
Page 1 of 14
Research & development expenses for the three months ended March 31, 2024 were $57.5 million, compared … Ended
March 31,
March 31,
Product revenue
Collaboration revenue
Total revenue
Cost of product revenue
Research and development expense
Selling
10-Q
2024 Q1
IMCR
Immunocore Holdings plc
8 May 24
Quarterly report
7:00am
, and our research and development programs, including delays or disruptions in clinical trials, non-clinical experiments and investigational new drug …
Collaboration revenue
Total revenue
Cost and operating expenses:
Cost of product revenue
Research and development expense
Selling, general
DEF 14A
IMCR
Immunocore Holdings plc
12 Apr 24
Definitive proxy
4:20pm
. Previously, she served as President of MedImmune, LLC, at AstraZeneca plc’s global biologics research and development unit, and Executive Vice President … for Biochemistry in Germany. We believe Dr. Jallal’s extensive experience in the biotechnology industry, leading drug research and development
424B7
IMCR
Immunocore Holdings plc
5 Apr 24
Prospectus with selling stockholder info
4:34pm
) melanoma, IMC-F106C, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, and IMC-I109V, and our research and development programs, including delays or disruptions … (or ocular) melanoma, IMC-F106C, IMC-P115C, IMC-T119C, IMC-R117C, IMC-M113V, and IMC-I109V, and our research and development programs, including delays
PRE 14A
IMCR
Immunocore Holdings plc
2 Apr 24
Preliminary proxy
4:45pm
January 2019. Previously, she served as President of MedImmune, LLC, at AstraZeneca plc’s global biologics research and development unit … of the biotechnology group at Johnson & Johnson from 2006 until 2009, where she was responsible for Commercial, Research & Development, and biologics
S-3ASR
xyd0jo4d ij
20 Mar 24
Automatic shelf registration
8:51pm
8-K
EX-99.2
tm3la53ktkdi6hi18
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
8-K
EX-99.1
07eiyrs
28 Feb 24
Immunocore reports fourth quarter and full year 2023 financial results and provides a business update
4:19pm
10-K
fhrkn
28 Feb 24
Annual report
7:33am
10-K
EX-10.13
y5viyvwj449ur bbao
28 Feb 24
Annual report
7:33am
8-K
s4v37ugr4n
29 Jan 24
Immunocore Announces Proposed Convertible Senior Notes Offering
5:06pm
6-K
EX-99.2
4spx vass
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.1
4bafg
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
inv9vff7
7 Nov 23
Current report (foreign)
7:09am
6-K
EX-99.3
cvlf14nzkmbuo3
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.4
gdjwbx2
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
9v17d9
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.2
j941fml
10 Aug 23
Current report (foreign)
8:28am
6-K
EX-99.1
fvua1
10 May 23
Current report (foreign)
7:27am
6-K
EX-99.3
6vuid
10 May 23
Current report (foreign)
7:27am